With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody transfer is considered when unexpected ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Hepatitis A may not be on your radar, but with the current LA County outbreak, you may want to reacquaint yourself with this ...

These are people who do not have hepatitis B but fail to develop enough antibodies after vaccination to prevent infection. It is estimated that between 5% and 10% of people vaccinated for ...

Chronic hepatitis B is a long-lasting, inflammatory liver disease caused ... Tobevibart is a monoclonal antibody developed by ...

Hepatitis A and B are the most common vaccine-preventable ... with nearly all subjects developing hepatitis A antibodies (anti-HAV) within 2 weeks. [3] However, a second dose of vaccine, given ...

The vaccine prompts a person’s immune system to create antibodies that can recognize and defend against the hepatitis B virus should there be a future exposure. The CDC recommends the hepatitis ...

Tests for hepatitis B can tell if you’re infected. They also look for proteins called antibodies in your blood to see if you were infected before but are now immune to the virus. The test for ...

“By harnessing the precision of these antibodies, it targets the large ... "GigaGen commences Phase I clinical trial of GIGA-2339 for hepatitis B treatment" was originally created and published ...